Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Prime Medicine, Inc. (Nasdaq: PRME) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a public biotechnology company, Prime Medicine uses forms such as Form 8-K, Form 10-Q, Form 10-K and proxy statements to report material events, financial results, governance matters and other information related to its Prime Editing gene editing platform and pipeline.
Recent Form 8-K filings for Prime Medicine have covered topics such as quarterly financial results and business highlights, preliminary cash and investment balances, underwritten public offerings of common stock, option repricing approvals, changes in executive leadership, and the posting of updated corporate presentations. These filings help investors understand how the company is funding research and development for programs in Wilson’s Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis and other areas, as well as how it manages equity compensation and corporate governance.
Definitive proxy materials, such as the company’s DEF 14A, describe matters submitted to stockholders, including proposals related to equity plans and special meetings. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide more detailed information on Prime Medicine’s operations, risk factors, research and development expenses, and other aspects of its business as a biotechnology issuer focused on Prime Editing-based therapies.
On Stock Titan, Prime Medicine filings are updated as they are made available through EDGAR. AI-powered tools summarize key points from lengthy documents, helping users quickly identify items such as new financing arrangements, changes in leadership roles, special stockholder meetings, and other material events disclosed in Forms 8-K and related exhibits. Users can also review filings that may include information about stock-based compensation, equity offerings, and other capital structure changes relevant to PRME shares.
Reine Allan reported acquisition or exercise transactions in this Form 4 filing.
Prime Medicine, Inc. reported that Chief Executive Officer Reine Allan received a grant of stock options for 1,300,000 shares of company stock. The options were awarded on February 26, 2026 and are held directly. They vest in substantially equal monthly installments, with 1/48 of the underlying shares vesting on each monthly anniversary of February 26, 2026, as long as Allan continues in service on each vesting date.
LEE ANN L. reported acquisition or exercise transactions in this Form 4 filing.
Prime Medicine, Inc. reported that Chief Technical Officer Lee Ann L. received a grant of stock options covering 375,000 shares of common stock. According to the terms, 1/48th of the option vests in substantially equal monthly installments starting on February 23, 2026, subject to her continued service, aligning this award with long-term employment and company performance.
Prime Medicine, Inc. reported that officer Alenson Carman acquired a stock option covering 140,000 shares of the company’s stock. This was recorded as a grant or award transaction.
According to the vesting terms, 1/48th of the option vests in substantially equal monthly installments on each monthly anniversary of February 23, 2026, conditioned on Carman’s continued service on each vesting date.
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 5,995,183 shares of Prime Medicine Inc. common stock, representing 3.3% of the class as of 12/31/2025. The firm has sole voting and dispositive power over all of these shares.
The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Prime Medicine. The filer also states that this report should not be construed as an admission that it is the beneficial owner of these securities.
Prime Medicine, Inc. furnished an updated corporate presentation on its investor website, with the materials attached as Exhibit 99.1. The presentation, dated January 2026, is provided under a Regulation FD disclosure to share information with the market in a broadly accessible way. The company states that this information is being furnished rather than filed, which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
Prime Medicine (PRME) filed its Q3 2025 10‑Q, highlighting a development‑stage profile with modest collaboration revenue and ongoing investment in programs. Total revenue was $1.2 million in the quarter, while the net loss was $50.6 million or $(0.32) per share. Year to date, revenue reached $3.8 million with a net loss of $155.1 million.
Operating expenses reflected pipeline progress and footprint expansion: R&D was $44.0 million and G&A was $11.2 million in Q3. Cash used in operations for the first nine months was $125.3 million. The balance sheet shows $71.4 million in cash and cash equivalents and $137.0 million in short‑term investments, totaling $213.3 million in cash, cash equivalents, and investments as of September 30, 2025. Management states this is sufficient to fund operations for at least twelve months from issuance.
In August 2025, the company completed a public offering of 43.7 million shares at $3.30 per share for $138.4 million in net proceeds. As of September 30, 2025, 180,309,471 shares were outstanding. Prime Medicine also recorded an $18.0 million research funding liability tied to external funding arrangements.
Prime Medicine (PRME) filed its Q3 2025 10‑Q, highlighting a development‑stage profile with modest collaboration revenue and ongoing investment in programs. Total revenue was $1.2 million in the quarter, while the net loss was $50.6 million or $(0.32) per share. Year to date, revenue reached $3.8 million with a net loss of $155.1 million.
Operating expenses reflected pipeline progress and footprint expansion: R&D was $44.0 million and G&A was $11.2 million in Q3. Cash used in operations for the first nine months was $125.3 million. The balance sheet shows $71.4 million in cash and cash equivalents and $137.0 million in short‑term investments, totaling $213.3 million in cash, cash equivalents, and investments as of September 30, 2025. Management states this is sufficient to fund operations for at least twelve months from issuance.
In August 2025, the company completed a public offering of 43.7 million shares at $3.30 per share for $138.4 million in net proceeds. As of September 30, 2025, 180,309,471 shares were outstanding. Prime Medicine also recorded an $18.0 million research funding liability tied to external funding arrangements.
Prime Medicine, Inc. (PRME) furnished an 8‑K to announce it issued a press release covering financial results and business highlights for the quarter ended September 30, 2025.
The disclosure was made under Item 2.02 and includes Exhibit 99.1 (Press Release dated November 7, 2025). The information is furnished and shall not be deemed filed under Section 18 of the Exchange Act, nor incorporated by reference, except as expressly stated by specific reference.
Prime Medicine’s common stock trades on The Nasdaq Global Market under the symbol PRME.
Prime Medicine, Inc. (PRME) furnished an 8‑K to announce it issued a press release covering financial results and business highlights for the quarter ended September 30, 2025.
The disclosure was made under Item 2.02 and includes Exhibit 99.1 (Press Release dated November 7, 2025). The information is furnished and shall not be deemed filed under Section 18 of the Exchange Act, nor incorporated by reference, except as expressly stated by specific reference.
Prime Medicine’s common stock trades on The Nasdaq Global Market under the symbol PRME.
Prime Medicine, Inc. furnished a corporate update through a new investor presentation posted on its website on September 8, 2025. The company made the presentation, dated September 2025, available as Exhibit 99.1 to this report under a Regulation FD disclosure item.
The material is being treated as furnished, not filed, which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
ARCH Venture group and certain affiliated funds and individuals report collective beneficial ownership of 18,486,894 shares of Prime Medicine common stock, representing 10.4% of the outstanding class on the basis described in this filing. The disclosure aggregates holdings across multiple ARCH entities and related partnerships and shows shared voting and dispositive power over those shares.
The filing also discloses that AVF XII purchased 3,030,300 shares at $3.30 per share in a public offering, for total consideration of $9,999,990, funded from AVF XII working capital. The amendment was filed because an issuer offering (an August 2025 issuance of 43,700,000 shares) changed the Reporting Persons' percentage ownership by one percent or more. The statement notes existing registration rights under an Amended and Restated Investors' Rights Agreement and that no Reporting Person was subject to disqualifying legal proceedings in the prior five years.
Prime Medicine (PRME) – Q2 2025 10-Q Snapshot
- Revenue: $1.1 m collaboration revenue (none in Q2 24); H1 revenue $2.6 m (+335% YoY).
- Expenses: R&D $41.4 m (-4% YoY); G&A $13.1 m (+4%). Total op-ex $54.5 m; loss from operations $53.4 m.
- Net loss: $52.6 m or $0.41/sh vs $55.3 m ($0.46) prior-year; H1 loss $104.5 m.
- Liquidity: Cash & cash equivalents $53.8 m (-70% YTD); investments $48.0 m; total liquid resources $101.8 m. Post-period Aug-25 equity raise added net $138.2 m, giving management >12-month runway.
- Balance sheet shifts: Right-of-use assets up to $120.2 m and non-current lease liabilities to $112.5 m following new Cambridge & Watertown facilities. Stockholders’ equity fell to $60.9 m (vs $153.1 m YE24) on continuing losses.
- Strategic updates: Focus pivots to in-vivo liver programs (Wilson’s, AATD) targeting INDs 1H-26; additional $24 m funding commitment from Cystic Fibrosis Foundation, incl. $6 m equity.
- Risks: Ongoing arbitration with Beam Therapeutics over AATD program could impose damages or halt development; high cash burn (~$90 m H1) and dilution from stock issuance remain concerns.
Management believes current cash plus August offering funds operations through at least Q3 26 while programs advance toward first clinical filings.